Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects
Cellular Oncology · 2025
DOI: 10.1007/s13402-025-01105-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2025. Verfasst von Meng-Jie Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China. Hauptthemen laut MEDLINE: Peptides, Cyclic, Receptor, EphA2, Lutetium, Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
- State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, and Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, 429 Zhangheng Road, Shanghai, 201203, China.
- General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
- College of Life Sciences, Nankai University, 94 Weijin Road, Tianjin, 300071, China.
- Department of Pathology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China. zhaowei_njmu@163.com.
- State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, and Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, 429 Zhangheng Road, Shanghai, 201203, China. xudong.kong…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, M. J., Chen, Y., Zhang, C., Bian, X., Zhang, X., Huang, S., Yang, B., Lu, S., Fu, X., Zhao, W., Kong, X. D., & Zhao, S. (2025). Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects. Cellular Oncology. https://doi.org/10.1007/s13402-025-01105-1
Vancouver
Zhang MJ, Chen Y, Zhang C, Bian X, Zhang X, Huang S, et al. Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects. Cellular Oncology. 2025. doi:10.1007/s13402-025-01105-1
BibTeX
@article{Zhang2025,
author = {Zhang, Meng-Jie and Chen, Yirong and Zhang, Caixia and Bian, Xiaofeng and Zhang, Xiangyang and Huang, Shijia and Yang, Bowen and Lu, Siyan and Fu, Xueting and Zhao, Wei and Kong, Xu-Dong and Zhao, Shuli},
title = {Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects},
journal = {Cellular Oncology},
year = {2025},
doi = {10.1007/s13402-025-01105-1}
}
EUVIMED